MENU
+Compare
PRLD
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$0.91
Change
+$0.02 (+2.25%)
Capitalization
48.82M

PRLD Prelude Therapeutics Forecast, Technical & Fundamental Analysis

Industry Biotechnology
PRLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for PRLD with price predictions
Dec 17, 2024

PRLD in -14.89% downward trend, declining for three consecutive days on December 13, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PRLD declined for three days, in of 274 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on PRLD as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for PRLD entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRLD's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PRLD advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

PRLD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.312) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). PRLD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (21.930) is also within normal values, averaging (260.687).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PRLD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PRLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PRLD is expected to report earnings to rise 10.23% to -47 cents per share on March 12

Prelude Therapeutics PRLD Stock Earnings Reports
Q4'24
Est.
$-0.47
Q3'24
Beat
by $0.04
Q2'24
Missed
by $0.04
Q1'24
Beat
by $0.07
Q4'23
Beat
by $0.04
The last earnings report on November 07 showed earnings per share of -43 cents, beating the estimate of -46 cents. With 314.57K shares outstanding, the current market capitalization sits at 48.82M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
175 Innovation Boulevard
Phone
+1 302 467-1280
Employees
128
Web
https://www.preludetx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XPL0.630.02
+4.10%
Solitario Resources Corp
FRPT146.38-0.68
-0.46%
Freshpet
MNST51.95-0.30
-0.57%
Monster Beverage Corp
MEC16.68-0.26
-1.53%
Mayville Engineering Company
CIFR7.23-0.16
-2.17%
Cipher Mining

PRLD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PRLD has been loosely correlated with AMRN. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PRLD jumps, then AMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRLD
1D Price
Change %
PRLD100%
-0.97%
AMRN - PRLD
35%
Loosely correlated
-0.80%
AXON - PRLD
35%
Loosely correlated
-2.09%
ABOS - PRLD
34%
Loosely correlated
-0.51%
GBIO - PRLD
34%
Loosely correlated
-6.03%
ATNM - PRLD
33%
Loosely correlated
-3.94%
More